The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma

Clinical Colorectal Cancer

Volumn 9, Issue 4, 2010, Pages 219-223

  Ewing, Gideon P ^a   Goff, Laura W ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

IGF1; IGF2; Phosphatidylinositol 3 kinase; Tyrosine kinase inhibitor

Indexed keywords

4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; A 926805; A 928605; AMG 479; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; AVE 1642; AXL 1717; BIIB 022; BMS 536924; BMS 554417; BMS 695735; BMS 754807; CETUXIMAB; CIXUTUMUMAB; CP 751871; GSK 1904529 A; IMC A 12; INSULIN RECEPTOR; IRINOTECAN; MK 0646; MONOCLONAL ANTIBODY; NVP AEW 541; OSI 906; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; R 1507; ROBATUMUMAB; SCH 717454; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; CYTOPENIA; DIARRHEA; FATIGUE; HUMAN; HYPERGLYCEMIA; MOLECULARLY TARGETED THERAPY; NAUSEA; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 77957777648     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.032     Document Type: Review

References (47)

1. Parkin DM. International variation. Oncogene 2004; 23:6329-40.
2. Mc Michael AJ, Mc Call MG, Hartshorne JM, et al. Patterns of gastro-intestinal cancer in European migrants to Australia: The role of dietary change. Int J Cancer 1980; 25:431-7.
3. Giovannucci E. Insulin and colon cancer. Cancer Causes Control 1995; 6:164-79.
4. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 1997; 336:633-40.
5. Khandwala HM, Mc Cutcheon IE, Flyvbjerg A, et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21:215-44.
6. Daughaday WH, Rotwein P Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev 1989; 10:68-91.
7. Le Roith D, Adamo M, Werner H, et al. Insulin like growth factors and their receptors as growth regulators in normal physiology and pathologic states. Trends Endocrinol Metab 1991; 2:134-9.
8. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4:505-18.
9. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999; 96:7324-9.
10. Tao Y, Pinzi V, Bourhis J, et al. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol 2007; 4:591-602.
11. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 2008; 8:915-27.
12. Sekharam M, Zhao H, Sun M, et al. Insulin-like growth factor I receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway Cancer Res 2003; 63:7708-16.
13. Tricoli JV, Rall LB, Karakousis CP, et al. Enhanced levels of insulin-like growth factor message RNA in human colon carcinomas and liposarcomas. Cancer Res 1986; 46:6169-73.
14. Rouyer-Fessard C, Gammeltoft S, Laburthe M. Expression of two types of receptor for insulin like growth factors in human colonic epithelium. Gastroenterology 1990; 98:703-7.
15. Pollak MN, Perdue JF, Margolese RG, et al. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 1987; 38:223-30.
16. Hakam A, Yeatman TJ, Lu L, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999; 30:1128-33.
17. Guo YS, Jin GF, Townsend CM, Jr, et al. Insulin-like growth factor-II expression in carcinoma in colon cell lines: implications for autocrine actions. J Am Coll Surg 1995; 181:145-54.
18. Zarrilli R, Pignata S, Romano M, et al. Expression of insulin-like growth factor (IGF)-II and IGF-I receptor during proliferation and differentiation of CaCo-2 human colon carcinoma cells. Cell Growth Differ 1994; 5:1085-91.
19. Adachi Y, Lee CT, Coffee K, et al. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 2002; 123:1191-204.
20. Clemmons DR, Van Wyk JJ, Ridgway EC, et al. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979; 301:1138-42.
21. Baris D, Gridley G, Ron E, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 2002; 13:395-400.
22. Orme SM, Mc Nally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom acromegaly study group. J Clin Endocrinol Metab 1998; 83:2730-4.
23. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3. J Natl Cancer Inst 1999; 91:620-5.
24. Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000; 9:345-9.
25. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-1, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92:1592-600.
26. Probst-Hensch NM, Yuan JM, Stanczyk FZ, et al. IGF-1, IGF-2, and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 2001; 85:1695-9.
27. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363:1346-53.
28. Burtrum D, Zhu Z, Lu D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63:8912-21.
29. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the in-hibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005; 11:2063-73.
30. Bladt F, Vrignaud P, Chiron M, et al. Preclinical evaluation of the anti-tumor activ-ity of the IGF1R-specific antibody AVE1642. Proc Amer Assoc Cancer Res 2006; 47: (abstract 1225).
31. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009; 28:3009-21.
32. Rodon J, Patnaik A, Stein M, et al. A phase I study of q3w R1507, a human mono-clonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors Presented at: the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics Molecular Targets Meet-ing; October 22-26, 2007. Abstract A77.
33. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti-insulin-like growth factor receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13:5834-40.
34. Tolcher AW, Rothenberg ML, Rodon J, et al. A phase I pharmacokinetic and phar-macodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007; 25(18 suppl):118s (abstract 3002).
35. Hidalgo M, Tirado Gomez M, Lewis N, et al. A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol 2008; 26(15 suppl):158s (abstract 3520).
36. Watkins DJ, Tabernero J, Schmoll HJ, et al. A phase II study of the anti-IGFR antibody MK-0646 in combination with cetuximab and irinotecan in the treat-ment of chemorefractory metastatic colorectal cancer. J Clin Oncol 2009; 27(15 suppl):199s (abstract 4127).
37. Pollak M, Eisenberg P, Karp D, et al. Safety and tolerability of the anti-IGF-1 receptor antibody CP 751,871 in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Presented at: the 98th Annual Meeting of the American Association for Cancer Research. April 14-18, 2007. Abstract LB-343.
38. Sarantopoulos J, Mita AC, Mulay M, et al. A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor antibody, in combination with panitumumab (P) or gemcitabine (G). J Clin Oncol 2008; 26(15 suppl): (abstract 3583).
39. Mc Caffery I, Tolcher A, Puzanov I, et al. Analysis of biomarkers during early phase clinical development of AMG 479, an investigational fully human monoclonal antibody antagonist of type 1 insulin-like growth factor receptor (IGF-1R). J Clin Oncol 2009; 27(15 suppl):157s (abstract 3545).
40. Tolcher AW, Patnaik A, Till E, et al. A phase I study of AVE1642, a humanized mono-clonal antibody IGF-1R (insulin like growth factor 1 receptor) antagonist, in patients with advanced solid tumor (ST). J Clin Oncol 2008; 26(15 suppl):173s (abstract 3582).
41. Wittman M, Carboni J, Attar R, et al. Discovery of a 1H-benzoimidazol-2- yl-1H-yridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem 2005; 48:5639-43.
42. Adachi Y, Piao W, Yamamoto H, et al. Treatment with IGF-I receptor tyrosine kinase inhibitor, NVP-AEW541, for gastrointestinal carcinomas. Presented at: the 98th Annual Meeting of the American Association for Cancer Research. April 14-18, 2007. Abstract 2372.
43. Sabbatini P, Rowand JL, Groy A, et al. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res 2009; 15:3058-67.
44. Velaparthi U, Wittman M, Liu P, et al. Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl) piperidin-4-yl)-4-methyl-1Hbenzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity. J Med Chem 2008; 51:5897-900.
45. Ji Q, Mulvihill MJ, Rosenfeld-Franklin M, et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor-dependent tumor growth in vivo. Mol Cancer Ther 2007; 6:2158-67.
46. Lindsay CR, Chan E, Evans TR, et al. Phase I dose escalation study of continuous oral dosing of OSI-906, and insulin like growth factor-1 receptor (IGF-1R) tyro-sine kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2009; 27(15 suppl):122s (abstract 2559).
47. Cartlidge SA, Chang Y, Lecomte-Raeber O, et al. MEDI-573: A fully human antibody to IGF-I and IGF-II for the treatment of solid tumor and hematological diseases. Presented at: the 100th Annual Meeting of the American Association for Cancer Research; April 18-22, 2009. Abstract 2802.